Organon & Co. (NYSE:OGN) Hits New 1-Year High – Time to Buy?

Organon & Co. (NYSE:OGN) shares reached a new 52-week high on Wednesday. The stock traded as high as $13.88 and last traded at $13.8550, with a volume of 151,651 shares traded. The stock had previously closed at $13.85.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $11.40.

Organon & Co. Stock Down 0.1%

The company has a quick ratio of 1.44, a current ratio of 2.02 and a debt-to-equity ratio of 7.11. The company has a fifty day simple moving average of $13.75 and a 200-day simple moving average of $11.58. The firm has a market cap of $3.63 billion, a P/E ratio of 18.18, a price-to-earnings-growth ratio of 1.27 and a beta of 1.53.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Friday, October 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.88 by $0.06. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.58 billion. On average, equities analysts anticipate that Organon & Co. will post 3.24 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Monday, November 9th will be issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, November 9th. Organon & Co.’s dividend payout ratio is currently 10.53%.

Institutional Investors Weigh In On Organon & Co.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System boosted its stake in shares of Organon & Co. by 34.8% in the first quarter. California State Teachers Retirement System now owns 327,075 shares of the company’s stock worth $1,959,000 after acquiring an additional 84,497 shares during the period. WINTON GROUP Ltd bought a new stake in Organon & Co. during the 2nd quarter valued at approximately $6,904,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Organon & Co. during the 2nd quarter valued at approximately $770,000. Orographic Financial Advisors LLC purchased a new position in Organon & Co. in the 1st quarter worth approximately $1,522,000. Finally, Sei Investments Co. lifted its holdings in Organon & Co. by 82.0% in the 1st quarter. Sei Investments Co. now owns 190,057 shares of the company’s stock worth $1,139,000 after purchasing an additional 85,657 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.